H.C. Wainwright reiterated its Buy rating on Kite Pharma Inc KITE on expectations that its cancer drug KTE-C19 would be approved in 2017 given more granular data on hand.
“Given that KTE-C19 has demonstrated positive results in DLBCL (including relapsed and refractory subgroups), PMBCL, and TFL patients, we expect the FDA to accept a broad label for KTE-C19, assuming it is approved later in 2017 for a conservative timeline of a 2018 launch,” analyst Corey Davis wrote in a note.
Davis maintains his $78 price target on the stock, which was down 7.63 percent at time of writing to $47.20.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.